GW Pharma Archives -

Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to

Wales is first UK country to fund GW’s Epidyolex for tuberous sclerosis

https://pharmaphorum.com/news/wales-is-first-uk-country-to-fund-gws-epidyolex-for-tuberous-sclerosis/

Trial of Jazz’ cannabis drug in glioblastoma will start next year

Phil Taylor cannabinoid, glioblastoma, GW Pharma, Jazz Pharmaceuticals, Oncology, Sativex 0 Comment

An investigator-led trial of Jazz Pharma’s cannabis extract-based drug Sativex in glioblastoma – an aggressive form of brain

Trial of Jazz’ cannabis drug in glioblastoma will start next year

https://pharmaphorum.com/news/trial-of-jazz-cannabis-drug-in-hard-to-treat-glioblastoma-will-start-next-year/

Market Access/ News

Jazz lifted by third EU approval for GW Pharma’s Epidyolex

Phil Taylor cannabis, Epidyolex, epilepsy, EU, GW Pharma, Jazz Pharmaceuticals, rare disease 0 Comment

GW Pharmaceuticals’ Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for

Jazz lifted by third EU approval for GW Pharma’s Epidyolex

https://pharmaphorum.com/news/jazz-lifted-by-third-eu-approval-for-gw-pharmas-epidyolex/

News/ News/ Sales and Marketing

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

Phil Taylor cannabis, Epidiolex, GW Pharma, Jazz Pharmaceuticals, M&A 0 Comment

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed

Jazz agrees $7.2bn deal to buy cannabis meds pathfinder GW Pharma

https://pharmaphorum.com/news/jazz-agrees-7-2bn-deal-to-buy-cannabis-meds-pathfinder-gw-pharma/

Market Access/ News/ News

AZ picks up $350m after selling hypertension drugs

Richard Staines AstraZeneca, Bayer, cancer, cardiology, GW Pharma, hypertension, multiple sclerosis 0 Comment

AstraZeneca has picked up a $350m windfall after selling off five hypertension medicines to generics specialist Atnahs Pharma.

AZ picks up $350m after selling hypertension drugs

https://pharmaphorum.com/news/az-picks-up-350m-after-selling-hypertension-drugs/

News/ News/ R&D

GW Pharma tops list of UK R&D spenders

Richard Staines AstraZeneca, Circassis, GlaxoSmithKline, GW Pharma, R&D 0 Comment

Pharma is leading the way in R&D investment in the UK, with cannabis medicine specialist GW splurging almost

GW Pharma tops list of UK R&D spenders

https://pharmaphorum.com/news/pharma-leads-rd-investment-in-uk/

Market Access/ News/ News

GW Pharma’s cannabis-derived epilepsy drug approved in EU

Richard Staines epilepsy, GW Pharma, neurology 0 Comment

GW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy. The

GW Pharma’s cannabis-derived epilepsy drug approved in EU

https://pharmaphorum.com/news/gw-pharmas-cannabis-derived-epilepsy-drug-approved-in-eu/

Market Access/ News/ News

GW confident epilepsy drug will get NHS funding despite NICE rejection

Richard Staines Epidyolex, epilepsy, GW Pharma, market access 0 Comment

The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis

GW confident epilepsy drug will get NHS funding despite NICE rejection

https://pharmaphorum.com/news/no-repeat-of/

News/ News/ R&D

Review finds medical benefits of cannabis-based drugs

Piotr Wnuk cannabinoid, cannabis, Epidolex, GW Pharma 0 Comment

The use of medical cannabis in the UK has moved a step closer, after the home secretary asked

Review finds medical benefits of cannabis-based drugs

https://pharmaphorum.com/news/review-finds-medical-benefits-cannabis-drugs/

Trending

GW Pharma

Login